PCRX logo

Pacira BioSciences, Inc. (PCRX) Cash from operations

annual CFO:

$189.39M+$34.74M(+22.46%)
December 31, 2024

Summary

  • As of today (September 17, 2025), PCRX annual cash flow from operations is $189.39 million, with the most recent change of +$34.74 million (+22.46%) on December 31, 2024.
  • During the last 3 years, PCRX annual CFO has risen by +$63.67 million (+50.65%).
  • PCRX annual CFO is now at all-time high.

Performance

PCRX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXcash flow metrics

quarterly CFO:

$12.01M-$23.45M(-66.12%)
June 30, 2025

Summary

  • As of today (September 17, 2025), PCRX quarterly cash flow from operations is $12.01 million, with the most recent change of -$23.45 million (-66.12%) on June 30, 2025.
  • Over the past year, PCRX quarterly CFO has dropped by -$41.22 million (-77.44%).
  • PCRX quarterly CFO is now -80.08% below its all-time high of $60.29 million, reached on September 30, 2021.

Performance

PCRX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXcash flow metrics

TTM CFO:

$134.52M-$41.22M(-23.46%)
June 30, 2025

Summary

  • As of today (September 17, 2025), PCRX TTM cash flow from operations is $134.52 million, with the most recent change of -$41.22 million (-23.46%) on June 30, 2025.
  • Over the past year, PCRX TTM CFO has dropped by -$59.84 million (-30.79%).
  • PCRX TTM CFO is now -34.01% below its all-time high of $203.84 million, reached on September 30, 2024.

Performance

PCRX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCRXcash flow metrics

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

PCRX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.5%-77.4%-30.8%
3 y3 years+50.6%-59.7%-6.6%
5 y5 years+168.6%+176.9%+286.1%

PCRX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+50.6%-77.7%at low-34.0%+6.4%
5 y5-yearat high+168.6%-80.1%+176.9%-34.0%+286.1%
alltimeall timeat high+374.3%-80.1%+159.4%-34.0%+294.8%

PCRX Cash from operations History

DateAnnualQuarterlyTTM
Jun 2025
-
$12.01M(-66.1%)
$134.52M(-23.5%)
Mar 2025
-
$35.46M(+7.0%)
$175.75M(-7.2%)
Dec 2024
$189.39M(+22.5%)
$33.13M(-38.6%)
$189.39M(-7.1%)
Sep 2024
-
$53.92M(+1.3%)
$203.84M(+4.9%)
Jun 2024
-
$53.24M(+8.4%)
$194.36M(+5.3%)
Mar 2024
-
$49.10M(+3.2%)
$184.62M(+19.4%)
Dec 2023
$154.65M(+6.5%)
$47.58M(+7.1%)
$154.65M(+3.7%)
Sep 2023
-
$44.44M(+2.2%)
$149.10M(+1.2%)
Jun 2023
-
$43.50M(+127.4%)
$147.32M(+10.2%)
Mar 2023
-
$19.13M(-54.5%)
$133.63M(-8.0%)
Dec 2022
$145.27M(+15.6%)
$42.04M(-1.4%)
$145.27M(+14.9%)
Sep 2022
-
$42.65M(+43.1%)
$126.45M(-12.2%)
Jun 2022
-
$29.81M(-3.2%)
$144.09M(-0.2%)
Mar 2022
-
$30.78M(+32.6%)
$144.41M(+14.9%)
Dec 2021
$125.72M(+63.2%)
$23.21M(-61.5%)
$125.72M(-15.7%)
Sep 2021
-
$60.29M(+100.1%)
$149.17M(+15.9%)
Jun 2021
-
$30.13M(+149.4%)
$128.66M(+55.2%)
Mar 2021
-
$12.08M(-74.1%)
$82.91M(+7.6%)
Dec 2020
$77.03M(+9.2%)
$46.67M(+17.3%)
$77.03M(+36.9%)
Sep 2020
-
$39.78M(-354.6%)
$56.27M(+61.5%)
Jun 2020
-
-$15.62M(-351.7%)
$34.84M(-52.4%)
Mar 2020
-
$6.21M(-76.0%)
$73.23M(+3.8%)
Dec 2019
$70.52M(+44.3%)
$25.90M(+41.1%)
$70.52M(+7.1%)
Sep 2019
-
$18.35M(-19.4%)
$65.84M(+2.7%)
Jun 2019
-
$22.76M(+550.6%)
$64.11M(+16.4%)
Mar 2019
-
$3.50M(-83.5%)
$55.06M(+12.7%)
Dec 2018
$48.87M(+174.8%)
$21.22M(+27.6%)
$48.87M(+9.6%)
Sep 2018
-
$16.63M(+21.3%)
$44.58M(+77.3%)
Jun 2018
-
$13.71M(-609.9%)
$25.14M(+66.6%)
Mar 2018
-
-$2.69M(-115.9%)
$15.09M(-15.2%)
Dec 2017
$17.79M
$16.93M(-703.0%)
$17.79M(-2.3%)
Sep 2017
-
-$2.81M(-176.8%)
$18.20M(-44.3%)
DateAnnualQuarterlyTTM
Jun 2017
-
$3.66M(>+9900.0%)
$32.70M(-10.6%)
Mar 2017
-
$6000.00(-100.0%)
$36.58M(+9.3%)
Dec 2016
$33.45M(+24.9%)
$17.35M(+48.5%)
$33.45M(+0.9%)
Sep 2016
-
$11.68M(+54.9%)
$33.14M(+36.5%)
Jun 2016
-
$7.54M(-341.6%)
$24.27M(-4.4%)
Mar 2016
-
-$3.12M(-118.3%)
$25.38M(-8.6%)
Dec 2015
$26.79M(+1.3%)
$17.04M(+504.7%)
$27.76M(+16.3%)
Sep 2015
-
$2.82M(-67.4%)
$23.87M(-20.3%)
Jun 2015
-
$8.65M(-1269.1%)
$29.96M(-6.1%)
Mar 2015
-
-$740.00K(-105.6%)
$31.89M(+20.6%)
Dec 2014
$26.44M(-161.8%)
$13.14M(+47.7%)
$26.44M(+277.9%)
Sep 2014
-
$8.90M(-15.9%)
$7.00M(-162.0%)
Jun 2014
-
$10.58M(-271.0%)
-$11.29M(-68.0%)
Mar 2014
-
-$6.19M(-1.7%)
-$35.28M(-17.5%)
Dec 2013
-$42.78M(-38.0%)
-$6.30M(-32.9%)
-$42.78M(-24.4%)
Sep 2013
-
-$9.38M(-30.0%)
-$56.59M(-3.1%)
Jun 2013
-
-$13.41M(-2.0%)
-$58.38M(-10.5%)
Mar 2013
-
-$13.69M(-31.9%)
-$65.19M(-5.6%)
Dec 2012
-$69.05M(+122.8%)
-$20.10M(+79.9%)
-$69.05M(+22.1%)
Sep 2012
-
-$11.18M(-44.7%)
-$56.55M(+5.0%)
Jun 2012
-
-$20.23M(+15.3%)
-$53.86M(+20.9%)
Mar 2012
-
-$17.55M(+131.0%)
-$44.56M(+43.7%)
Dec 2011
-$31.00M(+24.6%)
-$7.60M(-10.6%)
-$31.00M(+6.0%)
Sep 2011
-
-$8.49M(-22.2%)
-$29.24M(+5.7%)
Jun 2011
-
-$10.92M(+174.0%)
-$27.66M(+9.5%)
Mar 2011
-
-$3.99M(-31.7%)
-$25.27M(+1.6%)
Dec 2010
-$24.88M(+19.4%)
-$5.84M(-15.5%)
-$24.88M(+30.7%)
Sep 2010
-
-$6.91M(-19.0%)
-$19.04M(+57.0%)
Jun 2010
-
-$8.53M(+137.2%)
-$12.13M(+237.2%)
Mar 2010
-
-$3.60M
-$3.60M
Dec 2009
-$20.84M(-28.6%)
-
-
Dec 2008
-$29.19M(+117.3%)
-
-
Dec 2007
-$13.44M
-
-

FAQ

  • What is Pacira BioSciences, Inc. annual cash flow from operations?
  • What is the all time high annual CFO for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. annual CFO year-on-year change?
  • What is Pacira BioSciences, Inc. quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. quarterly CFO year-on-year change?
  • What is Pacira BioSciences, Inc. TTM cash flow from operations?
  • What is the all time high TTM CFO for Pacira BioSciences, Inc.?
  • What is Pacira BioSciences, Inc. TTM CFO year-on-year change?

What is Pacira BioSciences, Inc. annual cash flow from operations?

The current annual CFO of PCRX is $189.39M

What is the all time high annual CFO for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high annual cash flow from operations is $189.39M

What is Pacira BioSciences, Inc. annual CFO year-on-year change?

Over the past year, PCRX annual cash flow from operations has changed by +$34.74M (+22.46%)

What is Pacira BioSciences, Inc. quarterly cash flow from operations?

The current quarterly CFO of PCRX is $12.01M

What is the all time high quarterly CFO for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high quarterly cash flow from operations is $60.29M

What is Pacira BioSciences, Inc. quarterly CFO year-on-year change?

Over the past year, PCRX quarterly cash flow from operations has changed by -$41.22M (-77.44%)

What is Pacira BioSciences, Inc. TTM cash flow from operations?

The current TTM CFO of PCRX is $134.52M

What is the all time high TTM CFO for Pacira BioSciences, Inc.?

Pacira BioSciences, Inc. all-time high TTM cash flow from operations is $203.84M

What is Pacira BioSciences, Inc. TTM CFO year-on-year change?

Over the past year, PCRX TTM cash flow from operations has changed by -$59.84M (-30.79%)
On this page